Many pharmaceutical and biopharmaceutical companies are looking toward single-source supply partners to reduce risk and ensure an uninterrupted supply of critical, life-saving therapies.
With focus on more patient-centric delivery forms such as pre-filled syringes, auto-injectors, and more traditional vials, Sterile fill-finish is a mainstay in pharmaceutical manufacturing, and robotic platforms will be a true differentiator.
Since the transition period for EU regulation 536/2014 started this year, the focus has returned to meeting all of the demands that will change from the Directive that everyone has been accustomed to following.
Discover how planning for commercial launch requirements earlier in the clinical development cycle may reduce risk-to-launch timelines and avoid unnecessary delays.
What if you could eliminate avoidable delays and have a seamless transition from clinical trials to commercialization when launching your new drug?
As the R&D in oncological therapies continues to grow, so does demand for the specialist manufacturing, packaging and distribution of such products whether they contain highly potent actives or are biological in nature.
When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?
Start your PCI experience today.Your bridge between life-changing therapies and patients.
